Takashi Nagao Appointed President and Chief Executive Officer of Medicago
Medicago, a biopharmaceutical company headquartered in Quebec City, Canada, today announced Takashi Nagao as the company’s new President and Chief Executive Officer. Prior to becoming President and CEO, Mr. Nagao served as the Chairman of the Board of Medicago, where for the last four years, he has guided Medicago executives to get the company to where it is today.
Medicago, a research and development company for the last 20 years, is embarking on a transformative year, one that will see the company build on its R&D roots to become a company that also produces and commercializes vaccines and other immunotherapies. Mr. Nagao has extensive experience leading pharmaceutical companies through the pre-commercial and commercial process and is well positioned to ensure the successful launch of Medicago’s COVID-19 and influenza vaccines, subject to regulatory approvals. Mr. Nagao will continue Medicago’s evolution towards its goal of being a fully operational commercial entity, able to respond to the needs of the global public health community and medical authorities and professionals.
“Taking on this new role with Medicago during this exciting time is a great honour for me,” said Mr. Nagao, President and Chief Executive Officer, Medicago. “I want our employees, investors, and stakeholders such as the Government of Canada to know that I will put all my efforts into seeing our COVID-19 and influenza vaccines through to a successful launch to protect as many people as possible.”
From 2007 to 2017, Mr. Nagao oversaw the establishment of Mitsubishi Tanabe Pharma Corporation’s U.S. presence and led the team that successfully achieved NDA of RADICAVA®, the first FDA-approved drug in over 20 years for the patients with Amyotrophic Lateral Sclerosis (ALS). Prior to that, Mr. Nagao was a Managing Director in investment banking at J.P. Morgan and Deutsche Bank where he was responsible for global clients and leading equity and cross-border M&A transactions in the pharmaceutical and biotechnology sector in North America, Japan and Europe. He has an MBA from Harvard Business School.
Mr. Nagao succeeds Dr. Bruce D. Clark, who held the position of President and CEO of Medicago since 2017 and was instrumental in the development of Medicago’s COVID-19 vaccine candidate.
Medicago recently announced the start of Phase 2/3 clinical trial of its plant-derived VLP vaccine candidate for COVID-19 to evaluate its efficacy, safety, and immunogenicity, based on the positive Phase 1 results and subsequent allowance to advance to Phase 2/3 by the Canadian regulatory authorities. The company is also building a new facility in Quebec to increase Canada’s domestic capacity for manufacturing vaccines, producing up to a billion doses annually.
“Medicago is at an inflection point. We are moving from a research and development focused organization to become a commercial entity supplying vaccines to Canadians and people around the world,” said Mr. Nagao.
Medicago is a biopharmaceutical company and pioneer in plant-derived therapeutics. Founded in 1999 with the belief that innovative approaches and rigorous research would bring new solutions in healthcare.
Our mission is to improve global health outcomes by leveraging innovative plant-based technologies for rapid responses to emerging global healthcare challenges. Medicago is committed to advancing therapeutics against life-threatening diseases worldwide. Our team includes over 450 scientific experts and employees in Canada and the United States and academic affiliations in Europe and South Africa.
Medicago has previously demonstrated its capability to be a first responder in a flu pandemic. In 2009, the company produced a research-grade vaccine candidate against H1N1 in just 19 days. In 2012, Medicago manufactured 10 million doses of a monovalent influenza vaccine candidate within one month for the Defense Advanced Research Projects Agency (DARPA), part of the U.S. Department of Defense. In 2015, Medicago also demonstrated in principle that it could rapidly produce an anti-Ebola monoclonal antibody cocktail for the Biomedical Advanced Research and Development Authority (BARDA), part of the U.S. Department of Health and Human Services.
For more information: www.medicago.com
Media contact (English):
Alissa Von Bargen
Media contact (French):
+ 1 514 883-5948
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Esri Launches ArcGIS Platform27.1.2021 17:00:00 CET | Press release
Esri, the global leader in location intelligence, today announced the launch of ArcGIS Platform, a geospatial platform as a service (PaaS) for developers that need to integrate location capabilities into their apps, business systems, and products. ArcGIS Platform gives developers direct access to Esri's powerful location services using the APIs and web frameworks of their choice. "ArcGIS Platform lets users build their own products or integrate Esri services into existing software," said Jack Dangermond, Esri founder and president. "This PaaS makes it easier for software developers to access geospatial technology." "With the release of ArcGIS Platform, developers now have access to professional-grade content and capabilities they can readily plug into their apps, allowing them to stay on budget while delivering enormous value by reducing time to market," said David Cardella, Esri product manager for developer technologies. Scaling with developers and their apps, ArcGIS Platform lets cu
ONWARD Announces Publication in Nature Demonstrating Blood Pressure Stabilization in People with Spinal Cord Injury27.1.2021 17:00:00 CET | Press release
ONWARD today announced the publication of a study in the journal, Nature, which found targeted electrical spinal cord stimulation stabilizes blood pressure in people with spinal cord injury (SCI). “A serious and underrecognized result of spinal cord injury is unstable blood pressure, which can have devastating consequences that reduce quality of life and are life threatening. Unfortunately, there are no effective therapies for unstable blood pressure after spinal cord injury,” said Dr. Aaron Phillips, PhD, a member of the Hotchkiss Brain Institute and Libin Cardiovascular Institute at the Cumming School of Medicine (CSM) and co-lead author of the study. “We created the first platform to understand the mechanisms underlying blood pressure instability after spinal cord injury, which allowed us to develop a new cutting-edge solution.” Loss of movement and sensation are the most commonly known impacts of spinal cord injury, but SCI is also frequently accompanied by other effects that chall
Xsolla Establishes New Games Industry Collective, Xsolla Diamond Club27.1.2021 16:32:00 CET | Press release
Xsolla, the game commerce company powered by Transaction Engine and Business Engine to help developers and publishers market, sell, connect and optimize their games globally, is now accepting new members to the Xsolla Diamond Club, a professional community of like-minded video game developers and publishers looking to build successful businesses who can connect, learn proven methods and solve shared challenges. Membership to the collective is open to Xsolla clients and potential new partners. Diamond Club members can collaboratively tackle problems around funding, launching, distribution and monetization. To welcome new members, Xsolla is providing free tickets to upcoming sponsored virtual trade shows in 2021. Prospective members can apply to select the event that they would like to attend. After attending their first show, members will also have the benefit of purchasing discounted tickets to 40+ other future events in 2021, including: Taipei Game Show – January 28-31 Pocket Gamer –
C3 AI Reinvents No Code AI with the Introduction of C3 AI Ex Machina27.1.2021 15:26:00 CET | Press release
C3 AI (NYSE: AI), the world’s leading provider of enterprise AI software, today announced the general availability of C3 AI® Ex Machina, a next-generation predictive analytics application that empowers anyone to develop, scale, and produce AI-based insights without writing code. Analysts, operators, and subject matter experts across all industries and business functions are increasingly required to develop predictive and prescriptive insights compiled from vast and disparate datasets. While there are many no-code tools available that lower the barrier for users to build ML models and perform data analysis, none provide end-to-end capabilities that enable them to capture and process the volume and variety of data required, automatically generate interpretable AI models, and productize, deploy, and scale the results across their company. Current predictive analytics tools are typically complicated to use and limit the ability of their insights to drive real business outcomes. C3 AI Ex Ma
Philip Morris International Named to the 2021 Bloomberg Gender-Equality Index, Recognizing Company’s Commitment to Advancing Gender Equity27.1.2021 14:18:00 CET | Press release
Philip Morris International Inc. (PMI) (NYSE: PM) has today been added to the 2021 Bloomberg Gender-Equality Index (GEI) for its transparency in gender reporting and advancing women’s equity. This recognition underscores PMI’s work to progress gender equity in the workplace and to ensure equal opportunities for all employees. “I am delighted that PMI has been named to the 2021 Bloomberg Gender-Equality Index for our focus on advancing gender equity,” said Silke Muenster, Chief Diversity Officer at PMI. “We count on inclusion to better our organization and believe everyone has an important role to play in making PMI a more inclusive and diverse employer. From striving to improve our gender balance at all levels to maintaining our global leadership on equal pay, our efforts are not only an essential part of being a responsible corporate citizen and contributing to our shared global sustainability goals but also crucial to our progress toward delivering a smoke-free future.” The Bloomberg
Coty Announces Consolidation of Fragrance Manufacturing Operations with Intended Closure of Site in Cologne, Germany27.1.2021 14:10:00 CET | Press release
Coty Inc. (NYSE: COTY), one of the world’s leading beauty companies today announced the planned closure of its manufacturing site in Cologne, Germany. The move comes as Coty consolidates global fragrance operations. The Cologne site currently employs approximately 300 people and produces a range of fragrance products. The closure, which will occur in stages, will be preceded by the completion of all appropriate legal processes and is expected to be completed by Summer 2022. Richard Jones, Chief Global Supply Chain and R&D Officer at Coty, said: “We have taken this difficult decision to consolidate our fragrance manufacturing capacity in order to increase the efficiency of our operations. Coty is the world’s leader in fragrance, but our network has been operating over-capacity in recent years and the considerable impact of COVID-19 has accelerated the need to take action. This move will address the imbalance to increase our competitiveness and ensure we fully leverage our scale and rema
UnitedLex Integrates Microsoft Cloud to Globally Scale Digital Transformation of Legal Services27.1.2021 14:00:00 CET | Press release
UnitedLex, a leading technology and legal services company, has integrated Microsoft Cloud services to globally scale UnitedLex Vantage, a holistic, turnkey technology platform built to revolutionize the customer experience and transform the legal function into a first-class digital citizen. UnitedLex has integrated Microsoft solutions into its software portfolio since 2008 and has deep experience working closely with Microsoft. UnitedLex Vantage delivers a flexible, secure, and scalable platform, powering all enterprise legal workflows. Vantage comes with a vastly reduced implementation time (a matter of days versus months), a 20 percent increase in work efficiency, significant cost savings across overall legal and IT spend, and most crucially: new revenue opportunities for the business. UnitedLex Chief Technology Officer Sean Jennings said, “We are pleased to deepen our longstanding relationship with Microsoft. The Vantage platform represents a substantial investment for UnitedLex to